Full Press Release Details
MARLBOROUGH, Mass. , May 11, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16.
Following recent successes – including the U.S. Food and Drug Administration (FDA) approvals of the WATCHMAN™ Left Atrial Appendage Closure Device and the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System, as well as the commercial roll-out of the EMBLEM S-ICD System in Europe and of the Rhythmia™ Mapping System in the United States – the company's planned data presentations at HRS will underscore:
"The data presented at this meeting add substantially to the mounting evidence, experience and successes physicians are seeing with these novel therapies," said Kenneth Stein , M.D., chief medical officer, Rhythm Management, Boston Scientific. "We are pleased to continue delivering on our commitment to help improve the care of patients with cardiac rhythm disorders."
ABSTRACTS OF INTEREST (listed chronologically within product categories)
Subcutaneous Implantable Defibrillator (S-ICD) Data Presentations
Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Implantable Defibrillator (ICD) Data Presentations
WATCHMAN Device Data Presentations
Electrophysiology Data Presentations
All programs are listed in Eastern Time and will take place at the Boston Convention & Exhibition Center unless otherwise noted. For more information, visit Boston Scientific at booth #929.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, our products, data presentations and impact of data. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACTS Media: Trish Backes Boston Scientific Corporation 651-582-5887 (office) [email protected]
Investors: Susie Lisa , CFA Boston Scientific Corporation (508) 683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation